Sabestomig: Clinical Trials

3 trials of Sabestomig, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 completed. 2 Early Phase 1, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 12Active not recruiting 1, Completed 1
Phase 11Active not recruiting 1

Follow Sabestomig: new trials by email Literature Review of Sabestomig trials Research Report on Sabestomig

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
Rilvegostomig, Volrustomig, Sabestomig - Head and Neck Squamous Cell Carcinoma
Early Phase 1CompletedPresage Biosciences172024-05-222026-06-26
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Rilvegostomig, Volrustomig, Sabestomig - Solid Tumor
Early Phase 1Active not recruitingPresage Biosciences152021-07-262026-05-22
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
Datopotamab deruxtecan, Durvalumab, Carboplatin - Advanced or Metastatic NSCLC
Phase 1Active not recruitingAstraZeneca1552021-02-022026-10-27

Conditions studied

Head and Neck Neoplasms (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Lymphoma (1)  ·  Melanoma (1)  ·  Sarcoma (1)

Sponsors

Presage Biosciences (2)  ·  AstraZeneca (1)

Countries

United States (3)  ·  Belgium (1)  ·  Italy (1)  ·  Japan (1)  ·  Poland (1)  ·  Spain (1)  ·  Taiwan (1)  ·  Turkey (Türkiye) (1)

Results publications

PMID 36923556

NIH funding

2023 (1)